Form 4 for RCUS Arcus Biosciences, Inc.
Accepted 2022-03-10 00:00:00 ET · period of report 2022-03-07 · accession 0001209191-22-017967 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DI | 2022-03-10 | 2022-03-07 | RCUS | ROSEN TERRY J | CEO, Dir | G - Gift | $0.00 | -321.1K | 0 | -100% | $0 |
| D | 2022-03-10 | 2022-03-08 | RCUS | ROSEN TERRY J | CEO, Dir | A - Grant | $0.00 | +65.0K | 276.6K | +31% | $0 |
| D | 2022-03-10 | 2022-03-08 | RCUS | ROSEN TERRY J | CEO, Dir | A - Grant | $0.00 | +275.0K | 275.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-03-07 | G | D | 321,074 | $0.00 | 0 | I Rosen GRAT No. 2 | — | — | (F1) 321,074 shares were transferred to various family trusts in which the reporting person has no pecuniary interest, but retains voting and dispositive power over all of the shares transferred to each trust. The remaining 62,930 shares were transferred into the Rosen Family Trust in a transaction exempt from Section 16 reporting pursuant to Rule 16a13. |
| 2 | Common | Common Stock | 2022-03-08 | A | A | 65,000 | $0.00 | 276,570 | D | — | — | (F2) Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2022, subject to the Reporting Person's continued service to the Company. |
| 3 | Derivative | Stock Option (right to buy) | 2022-03-08 | A | A | 275,000 | $0.00 | 275,000 | D | $33.03 · — to 2032-03-07 | 275,000 Common Stock | (F4) The option is exercisable in 48 equal monthly installments after January 1, 2022, subject to the Reporting Person's continued service to the Company. |